FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

BEHIND THE RESEARCH Volume 348:975-976 March 13, 2003 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lack, G. Related Article by Leung, D. Y.M. PubMed Citation

In this issue of the Journal, Leung et al. (pages 986–993) report results with a new drug to reduce the risk of anaphylactic reactions to food. In a multicenter, phase 2 study, TNX-901, a monoclonal antibody to IgE, increased the threshold of sensitivity to peanut antigen to a level that should afford protection from unintended ingestions.

As a medical reporter, I interviewed Dr. Rebecca Gruchalla, who characterized the report as an "advance in the treatment of food allergy." Gruchalla, chair of the Food and Drug Reactions and Anaphylaxis Interest Section of the American Academy of Allergy, Asthma, and Immunology, said . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.